{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:15:40Z","timestamp":1783131340285,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009014","name":"Abbott Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009014","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Oscient Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ijantimicag.2014.12.034","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T08:15:26Z","timestamp":1424074526000},"page":"594-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations"],"prefix":"10.1016","volume":"45","author":[{"given":"J.M.","family":"Blondeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Shebelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Hesje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMoa012122","article-title":"Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia","volume":"346","author":"Davidson","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1086\/430829","article-title":"A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance","volume":"41","author":"Fuller","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2004.11782371","article-title":"The role of PK\/PD parameters to avoid selection and increase of resistance: mutant prevention concentration","volume":"16","author":"Blondeau","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet Dermatol"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.76.6.505","article-title":"The specific polysaccharide content of pneumonic lungs","volume":"76","author":"Frisch","year":"1942","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0160","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF01968060","article-title":"Bacterial counts in cerebrospinal fluid of children with meningitis","volume":"9","author":"Bingen","year":"1990","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0165","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/ajrccm\/142.5.1004","article-title":"Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients","volume":"142","author":"Fagon","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0170","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3476(76)80003-0","article-title":"Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis","volume":"88","author":"Feldman","year":"1976","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/47.2.129","article-title":"Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy","volume":"47","author":"Dagan","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0180","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2012"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0185","series-title":"Novel perspectives in antibacterial action","first-page":"15","article-title":"Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin","author":"Blondeau","year":"2002"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0190","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1179\/joc.2006.18.4.366","article-title":"Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones","volume":"18","author":"Blondeau","year":"2006","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.45.2.433-438.2001","article-title":"Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae","volume":"45","author":"Blondeau","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/430906","article-title":"Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?","volume":"41","author":"Doern","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2010.10.025","article-title":"Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Zhanel","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0210","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/jac\/dkg255","article-title":"Stretching the mutant prevention concentration (MPC) beyond its limits","volume":"51","author":"Smith","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0215","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14750708.2.6.813","article-title":"Differential impact on macrolide compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae","volume":"2","author":"Blondeau","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0220","series-title":"Proceedings of the 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Determination of the minimum inhibitory and mutant prevention concentration of telithromycin against clinical isolates of Streptococcus pneumoniae","author":"Borsos","year":"2005"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/jac\/dks461","article-title":"Minimal inhibitory and mutant prevention concentrations for azithromycin, clarithromycin and erythromycin with clinical isolates of Streptococcus pneumoniae","volume":"68","author":"Metzler","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0230","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.45.2.433-438.2001","article-title":"Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae","volume":"45","author":"Blondeau","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17476348.1.1.7","article-title":"MICs, MPCs and PK\/PDs: a match (sometimes) made in hosts","volume":"1","author":"Hesje","year":"2007","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0240","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1086\/376642","article-title":"Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia","volume":"37","author":"Anderson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0245","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/14750708.2.4.511","article-title":"Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs?","volume":"2","author":"Blondeau","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/43.suppl_2.43","article-title":"Bactericidal properties of moxifloxacin and post-antibiotic effect","volume":"43","author":"Boswell","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0255","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1179\/joc.2006.18.6.582","article-title":"Gemifloxacin for the management of community-acquired respiratory tract infections","volume":"18","author":"Blondeau","year":"2006","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.034_bib0260","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1600-0463.2005.apm_195.x","article-title":"Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens","volume":"113","author":"Drago","year":"2005","journal-title":"APMIS"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T23:30:03Z","timestamp":1589499003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0924857915000631"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.034","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}